RBF Capital’s Gyre Therapeutics GYRE Stock Holding History

RBF Capital’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13,613	Closed	-$51K	–	558
2022 Q3	$51K	Sell	13,613 -4,040	-23%	-$51.3K	﹤0.01%	512
2022 Q2	$138K	Hold	17,653	–	–	0.01%	483
2022 Q1	$87K	Hold	17,653	–	–	0.01%	505
2021 Q4	$121K	Hold	17,653	–	–	0.01%	504
2021 Q3	$544K	Sell	17,653 -3,439	-16%	-$113K	0.03%	346
2021 Q2	$685K	Buy	+21,092	New	+$724K	0.04%	319

Other funds holding GYRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

RBF Capital's GYRE Position: Q4 2022 in Review

RBF Capital sold out of Gyre Therapeutics (GYRE) in Q4 2022, closing a stake of 13,613 shares — an estimated $51K sold.

RBF Capital first reported a position in GYRE in Q2 2021 and held it in 6 quarters. The position peaked at $685K in Q2 2021. 34 funds tracked by Wall St. Rank hold GYRE as of Q4 2022.

RBF Capital reported no remaining Gyre Therapeutics position as of Q4 2022 after selling out during the quarter.
RBF Capital sold 13,613 Gyre Therapeutics shares in Q4 2022, an estimated $51K.
RBF Capital first reported a position in Gyre Therapeutics in Q2 2021 and held it in 6 quarters.
RBF Capital's Gyre Therapeutics position peaked at $685K in Q2 2021.
34 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2022.

Based on RBF Capital's 13F filing for Q4 2022, filed 14 Feb 2023.